News

Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines

Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines

Be Bio Announces Appointment of Jay Backstrom, M.D., M.P.H., to Board of Directors

Be Bio Appoints Leading Cell & Gene Therapy Executives, Krishnan Viswanadhan as President & Chief Operating Officer, and Brad Hartman as Chief People Officer

Be Bio Announces Appointment of Cell and Gene Therapy Veterans Joanne Smith-Farrell, Ph.D., as Chief Executive Officer and Rick Morgan, Ph.D., as Chief Scientific Officer

Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines

Be Bio, Resilience to manufacture engineered B cells for rare diseases

Resilience inks manufacturing pact with ARCH-backed cell therapy startup as it preps for the long haul

B round for Be Bio’s B cells: Arch leads $130M funding for cell engineering start-up

Arch leads $130M round for cell therapy startup targeting cancer, rare disease

ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer

Be Bio uses Arch Venture-led $130M financing round to harness ‘power of the B cell’

Can B cells break the boundaries of cell therapy? Longwood startup has $52M to prove a new engineering tech

Be Biopharma debuts with $52M to advance engineered B-cell therapies

Longwood, Atlas Venture inject $52M into cell therapy startup

Transcriptional regulation of memory B cell differentiation

Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells

Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells

Be Bio and Resilience Announce Strategic Collaboration to Manufacture Engineered B Cells, a New Class of Cellular Medicines

Be Bio Closes $130 Million Financing to Pioneer Engineered B Cells, a New Class of Cellular Medicines

Be Bio Announces Appointment of Jay Backstrom, M.D., M.P.H., to Board of Directors

Be Bio Appoints Leading Cell & Gene Therapy Executives, Krishnan Viswanadhan as President & Chief Operating Officer, and Brad Hartman as Chief People Officer

Be Bio Announces Appointment of Cell and Gene Therapy Veterans Joanne Smith-Farrell, Ph.D., as Chief Executive Officer and Rick Morgan, Ph.D., as Chief Scientific Officer

Be Biopharma Launches with $52 Million Series A Financing to Advance B Cells as Medicines

Be Bio, Resilience to manufacture engineered B cells for rare diseases

Resilience inks manufacturing pact with ARCH-backed cell therapy startup as it preps for the long haul

B round for Be Bio’s B cells: Arch leads $130M funding for cell engineering start-up

Arch leads $130M round for cell therapy startup targeting cancer, rare disease

ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer

Be Bio uses Arch Venture-led $130M financing round to harness ‘power of the B cell’

Can B cells break the boundaries of cell therapy? Longwood startup has $52M to prove a new engineering tech

Be Biopharma debuts with $52M to advance engineered B-cell therapies

Longwood, Atlas Venture inject $52M into cell therapy startup

Transcriptional regulation of memory B cell differentiation

Factors Affecting Early Antibody Secreting Cell Maturation Into Long-Lived Plasma Cells

Engineering Protein-Secreting Plasma Cells by Homology-Directed Repair in Primary Human B Cells

B lymphocytes and cancer: a love-hate relationship

Meet the people behind the headlines